|
Friday, April 28
5:00pm–6:00pm
1600A—Bone Marrow Failure—Treatment of
Acquired Aplastic Anemia in Children
ASPHO Workshop
Golden Gate Hall A2-3, SF Marriott
Chairs: Akiko Shimamura, Children’s Hospital, Boston, MA; and
Adrianna Vlachos, Schneider Children’s Hospital, New Hyde
Park, NY
This session will focus on
acquired marrow failure. The first presentation will focus on
the treatment and management of acquired aplastic anemia in
children. Studies pertaining to the pediatric population will
be highlighted. Issues guiding the choice of therapy at
diagnosis, at relapse and for refractory disease will be
discussed. The second presentation will discuss the diagnosis
and management of paroxysmal nocturnal hemoglobinuria (PNH) in
the pediatric population. The clinical significance and
management of PNH clones arising in patients with aplastic
anemia will be discussed.
-
Treatment Options and Management
of Aplastic Anemia in Children
Peter Kurre, Oregon Health & Science University, Portland, OR
-
Paroxysmal Nocturnal
Hemoglobinuria in Pediatric Patients
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
5:00pm–6:00pm
1610A—Thrombosis—Going with the Flow:
Anticoagulation Issues in Children with Congenital Heart
Disease
ASPHO Workshop
Golden Gate Hall B2-3, SF Marriott
Chairs: Patricia Massicotte, University of Alberta Hospital, Edmonton,
AB, Canada; and Lori Luchtman-Jones, Washington University,
St. Louis, MO
Warfarin is commonly used in
children with congenital heart disease (CHD). There are many
challenges with the use of this anticoagulant in children.
Ultimate dosing depends on the individuals genetic
composition. Child-focused education on warfarin will improve
compliance, efficacy and safety. The hematologist with
expertise in anticoagulation can provide child-focused
education on anticoagulation and offer the cardiovascular team
management solutions for managing the complex issues
associated with anticoagulation in children with CHD.
-
Case Study and Discussion
Therese Giglia, Schneider Children's Hospital, New Hyde Park, NY
-
Child-Focused Education Package:
Warfarin
Mary Bauman, Stollery Children's Hospital, Edmonton, AB, Canada
-
Pharmacogenomics of Warfarin
Lori Luchtman-Jones, Washington University, St. Louis, MO
-
Keep the Flow: Hematologists as
Part of the Cardiovascular Team in Children with
Congenital Heart Disease
Therese Giglia, Schneider Children's Hospital, New Hyde Park, NY
-
Panel Discussion
7:00pm–9:00pm
1850A—Pediatric Hematology/Oncology
Training Program Directors' Dinner Meeting
ASPHO Dinner
Yerba Buena Gardens Salons 10-12, SF Marriott
Saturday, April 29
7:00am–8:00am
2050A—Hemorrhagic Disorders
ASPHO Workshop
Golden Gate Hall A2-3, SF Marriott
Chairs: Pedro A. de Alarcon, St. Jude Research Hospital, Memphis, TN;
and Marilyn Manco-Johnson, Mountain States Hemophilia
Treatment Center, Aurora, CO
This workshop will present
current information about hemophilia A and B inhibitors and
therapy with immune tolerance, including a discussion of
Factor VIII inhibitors and the International ITI Study, Factor
IX inhibitors and anaphylaxis syndrome.
-
Introduction
-
Factor VIII Inhibitors and
International ITI Study
Donna D. DiMichele, New York Presbyterian Hospital, New York, NY
-
Factor IX Inhibitors and
Anaphylasis Syndrome
Amy D. Shapiro, Indiana Hemophilia and Thrombosis Center, Indianapolis,
IN
-
Discussion and Concluding Remarks
7:00am–8:00am
2055A—Histiocytosis
ASPHO Workshop
Golden Gate Hall C2-3, SF Marriott
Chairs: James Whitlock,Vanderbilt Children's Hospital, Nashville, TN;
and Alexandra Filipovich, Children’s Hospital Medical
Center, Cincinnati, OH
This workshop will present recent
developments in the biology, diagnosis, evaluation and
management of children with Langerhans cell histiocytosis and
hemophagocytic lymphohistiocytosis, including updates from
recently completed and ongoing international clinical trials
for these disorders. The availability of new internet-based
patient registries will also be discussed.
-
Update on Hemophagocytic
Lymphohistiocytosis
Alexandra H. Filipovich, Children's Hospital Medical Center,
Cincinnati, OH
-
Update on Langerhans Cell
Histiocytosis
James A. Whitlock, Vanderbilt Children's Hospital, Nashville, TN
-
Update on Rare Histiocytosis
Registries
James A. Whitlock, Vanderbilt Children's Hospital, Nashville, TN
8:00am–11:00am
2100—Adult Stem Cells—A Primer for the
Clinician
PAS/ASPHO Mini Course
Room 3014, Moscone West
Chairs: Jakub Tolar, University of Minnesota, Minneapolis, MN; and
Mervin C. Yoder, Jr., Indiana University School of Medicine,
Indianapolis, IN
Target Audience:
Hematologists/oncologists, endocrinologists, basic scientists
and neurologists.
Adult stem cells represent a
technology that is being intensively investigated currently,
and this research may have wide implications for human health.
This mini course will focus on recent research and potential
applications in human health.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
Mervin C. Yoder, Indiana
University School of Medicine, Indianapolis, IN
-
Multipotent Adult Progenitor
Cell: Hype or Reality?
Catherine M. Verfaillie, University of Minnesota, Minneapolis, MN
-
Mesenchymal Stem Cell: Harnessing
the Power of Adult Stem Cells To Repair Tissues
Darwin Prockop, Tulane University Health Science Center, New Orleans,
LA
-
Hierarchy of Endothelial
Progenitors in Human Blood and Blood Vessels
David A. Ingram, Indiana University School of Medicine, Indianapolis,
IN
-
Cancer Stem Cell: Concept of
Human Leukemic Development
Craig T. Jordan, James P. Wilmot Cancer Center, University of Rochester
School of Medicine, Rochester, NY
Sponsored jointly by
the American Society of Pediatric Hematology/Oncology and the
Pediatric Academic Societies
8:15am–10:15am
2190A—Difficult Coagulation Consults
ASPHO Symposium
Room 3016-3018, Moscone West
Chairs: Guy Young, Children’s Hospital of Orange County, Mattel
Children's Hospital at UCLA, Orange, CA; and Prasad Mathew,
University of New Mexico, Albuquerque, NM
Pediatric
hematologist/oncologists are frequently asked to consult on
patients with a variety of coagulation problems. While some of
these are fairly straightforward, there are some that create
significant diagnostic and therapeutic dilemmas. This session
will focus on three such areas. The first lecture will discuss
the pre-operative assessment for coagulation disorders in both
asymptomatic and symptomatic children. This lecture will focus
on what if any evaluation is needed and how to proceed if
screening tests are abnormal. The second talk will discuss the
difficulties in diagnosing and treating rare bleeding
disorders, including rare factor deficiencies and rare
platelet function disorders. The last presentation will focus
on the management of patients who wish to avoid blood products
(for religious beliefs, for example). This lecture will
discuss the available strategies for the avoidance of blood
products both in the surgical and non-surgical setting. After
attending this session, it is expected that the learner will
be able to: 1) describe the approach to the pre-operative
evaluation of children undergoing surgery from the standpoint
of potential bleeding complications; 2) discuss the diagnosis
and treatment of rare bleeding disorders; 3) identify
strategies for the avoidance of blood products for
patients/families wishing to avoid the use of such products.
-
Introduction
-
Pre-operative Evaluation for
Coagulation Disorders
Marilyn J. Manco-Johnson, University of Colorado Denver, The Health
Sciences Center, Aurora, CO
-
Rare Bleeding Disorders
Diane J. Nugent, Children's Hospital of Orange County, Orange, CA
-
Bloodless Medicine: Strategies To
Avoid/Minimize Transfusion of Blood Products
Aryeh Shander, Englewood Hospital and Medical Center, Englewood, NJ
-
Discussion
10:30am–11:15am
2300A—Best of SIOP (International Society
of Paediatric Oncology)
ASPHO Platform Session
Room 3020, Moscone West
Chairs: To be announced
-
Updated Therapeutic Results of
286 Burkitt's Lymphoma in French African Pediatric
Oncology Group (FAPOG)
Mhamed Harif
-
Ommission of Required
Radiotherapy in Group III Rhabdomyosarcoma Patients
Ori Shokek, Johns Hopkins Oncology Center, Baltimore, MD
10:30am–12:30pm
2330—Hematology/Oncology I
PAS/ASPHO Platform Session
Room 3016-3018, Moscone West
Chairs: Scott Cameron and Jorge DiPaola
12:00pm–3:00pm
2505—Embryonic Stem Cells: A Primer for
Clinicians
PAS Mini Course
Room 3014, Moscone West
Chair: Michael T. Longaker, Stanford University, Stanford, CA
Embryonic stem cells offer
incredible promise for treating diseases affecting both
children and adults. This mini course will provide an overview
of stem cells and a basic understanding of how to derive human
embryonic stem cells, recent research and ethical
considerations. After attending this session, attendee will
have a better understanding of: 1) what are embryonic stem
cells; 2) how human embryonic stem cells are derived; 3)
recent progress in human embryonic stem cell research; 4)
ethical considerations in human embryonic stem cells.
-
Stem Cells: Embryonic, Adult and
Cancer
Michael T. Longaker, Stanford University, Stanford, CA
-
What It Takes Clinically To Get
an Embryonic Stem Cell
Linda C. Giudice, University of California, San Francisco, San
Francisco, CA
-
What Can You Do with an Embryonic
Stem Cell in Research
Renee Reijo Pera, University of California, San Francisco, San
Francisco, CA
-
Ethical and Oversight
Considerations in Human Embryonic Stem Cell Research
Hank Greely, Stanford University, Stanford, CA
-
Panel Discussion
Supported in part by an unrestricted educational grant from
Treuman Katz Center for Pediatric Bioethics - Seattle
Children's Hospital
12:45pm–2:45pm
2550A—Challenges in Neonatal Care:
Coagulation Disturbances, IVH and Bleeding Control
ASPHO Industry Sponsored Symposium
Yerba Buena Gardens Salon 8, SF Marriott
Chair: Lu-Ann Papile, University of New Mexico Children’s Hospital,
Albuquerque, NM
Premature infants are at high
risk for cerebral hemorrhage because of their fragile cerebral
vasculature and their compromised ability to self-regulate
cerebrovascular responses. This symposium will review the
hematology of neonates and will discuss the pathophysiology of
and treatment options for intraventricular hemorrhage and
other hemorrhagic conditions in neonates.
Supported by a grant from Novo Nordisk Pharmaceuticals, Inc.
12:45pm–2:45pm
2551A—Advances in the Diagnosis and
Management of Patients with Hematologic Disorders
ASPHO Industry Sponsored Symposium
Yerba Buena Gardens Salon 9, SF Marriott
Chair: Elliot Vichinsky, Chief, Department of Hematology &
Oncology, Children’s Hospital and Research Center, Oakland,
CA
Emerging data on the treatment of
pediatric anemias continue to mature and evolve. In this
symposium, distinguished faculty will review considerations
for management of patients with pediatric anemias, and help
increase physicians’ awareness of current and future
treatment options for these patients and their applications in
the field of pediatric hematology.
The benefits of transfusion
therapy as supportive care for patients with thalassemia,
sickle cell disease, and other transfusion-dependent disorders
are well established, both for improving quality of life and
prolonging survival. However, these benefits are often limited
by the accumulation of iron in the body.
Transfusion-associated iron overload negatively impacts the
function of the liver, heart, and endocrine organs, resulting
in increased morbidity and mortality. Although treatments for
iron overload can be highly effective, their use can be
limited by difficulty of administration and poor compliance.
Thus, effective, more convenient iron chelation therapy is a
growing need.
Supported by a grant from Novartis Oncology
1:00pm–3:00pm
2620—Neonatal Hematology–Immunology
PAS Poster Symposium
Room 3024, Moscone West
Chairs: Michael P. Sherman and Eric J. Werner
2:15pm–5:15pm
2700—Educating Pediatric Fellows in a
Competency-Based World
PAS/APPD Mini Course
Room 2007, Moscone West
Chairs: Susan Guralnick, Stony Brook University Medical Center, Stony
Brook, NY; and Joseph Gilhooly, Oregon Health and Science
University, Portland, OR
Target Audience: Attendees
involved with fellowship programs.
Competency-based education is now
the standard for residency education. Residency programs have
integrated the ACGME Core Competencies into their curricula
and assessment methods. It is now time for fellowships to
enter the “competency” arena, and there is much to be
accomplished. This program will focus on several areas of
fellowship education including: the new RRC common
requirements for subspecialty training, development of a
competency-based fellowship curriculum, competency-based
assessment tools, and pediatric subspecialty fellows as
teachers. Attendees are encouraged to bring tools and ideas
for discussion and development. Attendees should leave with
useful materials to bring back to their home programs.
-
Overview
Susan Guralnick, Stony Brook University Medical Center, Stony Brook, NY
Joseph Gilhooly, Oregon Health
& Science University, Portland, OR
-
A Brave New World! New Common
Requirements for Subspecialty Training—Implementing the
Competencies
Carol Carraccio, Professor of Pediatrics and Associate Chair for
Education, University of Maryland School of Medicine,
Baltimore, MD
-
"Survivor ACGME"—Fellowship
Competencies in Action
Joseph Gilhooly, Oregon Health & Science University, Portland, OR
John D. Mahan, Children’s
Hospital, The Ohio State University, Columbus, OH
-
Turning to Fellows as Teachers:
From Curricula to Evaluation
Nancy D. Spector, St. Christopher's Hospital for Children,
Philadelphia, PA
Susan Guralnick, Stony Brook
University Medical Center, Stony Brook, NY
Sponsored jointly by
the Association of Pediatric Program Directors and the
Pediatric Academic Societies
Supported by an unrestricted educational grant from Dey,
L.P.
2:15pm–5:15pm
2705—Vitamin D: More Than Just Calcium and
Bone
PAS/LWPES Mini Course
Room 3007-3009, Moscone West
Chairs: Catherine M. Gordon, Children's Hospital of Boston, Boston, MA;
and Linda A. DiMeglio, Indiana University, Indianapolis, IN
Target Audience: General
pediatricians, gastroenterologists, endocrinologists and
hematologists/oncologists.
The understanding of the role of
vitamin D in health and illness is becoming more complex. Both
skeletal and extra-skeletal actions have been described, and
vitamin D analogs are being explored for their anti-proliferative
effects. The attendee will gain both clinically relevant
epidemiological knowledge as well as review the calcemic and
non-calcemic actions of Vitamin D.
-
What Is the Evidence for Vitamin
D Deficiency in Children?
Frank R. Greer, University of Wisconsin, Madison, WI
-
Vitamin D and Extra-Skeletal
Actions in Health
Michael F. Holick, Boston University School of Medicine, Boston, MA
-
Non-calcemic Actions of Vitamin D
Receptor Ligands
Sunil Nagpal, Women's Health & Musculoskeletal Biology,
Collegeville PA
Sponsored jointly by
the Lawson Wilkins Pediatric Endocrine Society and the
Pediatric Academic Societies
3:00pm–5:00pm
2710A—Hematopoietic Cell
Transplantation—An Update
ASPHO Symposium
Room 3016-3018, Moscone West
Chairs: Jakub Tolar and K. Scott Baker, University of Minnesota,
Minneapolis, MN
The program will begin with a
review of unrelated umbilical cord blood transplantation, now
a common practice in the treatment of pediatric malignancies.
The program will follow with a presentation of the most recent
data on reduced intensity hematopoietic cell transplantation
for treatment of malignant and non-malignant diseases in
children. The symposium will conclude with an overview of
immune implications of mesenchymal stem cell infusion,
including their use for graft versus host disease prophylaxis
and treatment. Cellular therapy has yielded notable successes
in the past decade and holds considerable promise, and one
should walk away from the session with a realistic overview of
the possibilities and limitations of cellular therapy for
childhood cancer.
After attending this session, it
is expected that the learner will be able to:
1. Identify efficacious cellular
therapy approaches.
2. Recognize the limitations of cellular therapy for childhood
cancer.
-
Introduction
Jakub Tolar, University of Minnesota, Minneapolis, MN
-
Umbilical Cord Blood
Transplantation: Current Practice and Future Innovations
John E. Wagner, University of Minnesota Medical School, Minneapolis, MN
-
Non-myeloablative Hematopoietic
Cell Transplantation in Children
Morris Kletzel, Northwestern University Feinberg School of Medicine,
Chicago, IL
-
Immunobiology of Mesenchymal Stem
Cells
Katarina Le Blanc, Karolinska University, Stockholm, Sweden
-
Question and Answer Session
3:15pm–5:15pm
2735—Update on Therapeutic Monoclonal
Antibodies
PAS Topic Symposium
Room 3014, Moscone West
Chair: E. Richard Stiehm, UCLA School of Medicine, Los Angeles, CA
Target Audience: Immunologists,
rheumatologists, hematologists, oncologists and general
pediatricians.
The first talk will be an
overview of the various therapeutic monoclonals and some
general principles of their use. Then a discussion of
Rituximab in refractory immune cytopenias and other disorders
will be presented. Then the use of anti-tumor necrosis factor
treatment including infliximab and adalimumab (Ramicade and
Humira) for rheumatic diseases in children. The final talk
will discuss the adverse effects of these therapies and some
projections for the future. Discussion will be held after each
presentation.
-
Overview
E. Richard Stiehm, Mattel Children's Hospital at UCLA, Los Angeles, CA
-
Use of Anti-CD20 (Rituximab) in
Hematology and Autoimmunity
James B. Bussel, New York Hospital, Cornell Medical Center, New York,
NY
-
Use of Anti-TNF and Other
Cytokine Inhibitors in Rheumatology and Related Illnesses
Christy Irene Sandborg, Stanford University Medical Center, Stanford,
CA
-
The Downside and Future of
Monoclonal Antibody Therapy
Susan Lee, University of California, San Diego, CA
4:00pm–7:30pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
4:00pm–7:30pm
Author Attendance: 5:15pm–7:15pm
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
5:15pm–7:15pm
Poster Session I and PAS Opening Reception
PAS Poster Session
Levels 1 and 2, Moscone West
Level 1:
– Developmental Biology
– Endocrinology
– Hematology–Oncology
– Neonatal Infectious Diseases
– Neonatology
– Nephrology
Level 2:
– Cardiology
– Developmental–Behavioral Pediatrics
– General Pediatrics
– Medical Education
– Neurology
Includes:
-
SPR Student Research Award:
Resuscitation of Non-Viable Infants: Will Neonatologists'
Practice Change After the Born-Alive Infant Protection
Act?
Mya Sendowski, University of California, San Francisco, CA
Sunday, April 30
7:00am–8:00am
3060A—Practice Management—Results of the
2005 ASPHO Compensation Survey
ASPHO Workshop
Golden Gate Hall A1, SF Marriott
Chair: Timothy C. Griffin, Cook Children's Medical Center, Fort Worth,
TX
In the spring of 2005, ASPHO
conducted a survey of its membership regarding compensation.
The preliminary results of this survey will be presented, and
members will have an opportunity to ask questions and provide
insights into the results in an open forum.
7:00am–8:00am
3065A—Young Investigators
ASPHO Workshop
Golden Gate Hall A2, SF Marriott
Chair: Kathleen M. Sakamoto, University of California Los Angeles, Los
Angeles, CA
This workshop will focus on
career options in pediatric hematology–oncology. Pediatric
hematologists–oncologists representing basic/translational
research, clinical research and industry will discuss their
experiences and the reasons for their career choices. The
workshop provides an opportunity for fellows and junior
faculty to interact with each other and established faculty
members and to discuss issues related to career decisions,
research directions and career development.
-
Clinical Research—Building Your
Career from the Ground Up
Smita Bhatia, City of Hope Medical Center, Duarte, CA
-
Choosing a Career in
Basic/Translational Research
Kathleen M. Sakamoto, Mattel Children's Hospital at UCLA, Los Angeles,
CA
-
Choosing a Career in Industry
Anne E. Hagey, Oncology Cytotoxics, Abbott Laboratories, Abbott Park,
IL
-
Discussion
8:00am–9:30am
3150—Hematology/Oncology II
PAS/ASPHO Platform Session
Room 3016-3018, Moscone West
Chairs: Yigal Dror and James A. Whitlock
Includes
-
SPR Fellow's Clinical Research
Award: DNA Repair Polymorphism and Outcome of Treatment
for Acute Myelogenous Leukemia (AML)
Deepika Bhatla, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
-
CXCR4 Inhibition Leads to
Decreased Adhesion and Fewer Metastases in Osteosarcoma
Su Young Kim, National Institutes of Health, Bethesda, MD
9:45am–11:45am
3300A—Pure Red Cell Aplasia
ASPHO Symposium
Room 3016-3018, Moscone West
Chair: Jeffrey M. Lipton, Schneider Children’s Hospital, New Hyde
Park, NY
The pure red cell aplasias (PRCA)
represent a form of bone marrow restricted to the erythroid
lineage. Research has led to new insights into the molecular
basis of erythroid development. Transcriptional regulation of
erythropoiesis will be discussed in this symposium. In
pediatrics, intrinsic stem/progenitor cell defects are the
most important cause of red cell failure. One of the most
common forms of pure red cell aplasia in pediatric patients is
Diamond-Blackfan Anemia. The clinical and molecular basis of
this disease will be presented. Congenital dyserythropoietic
anemias (CDA) are rare forms of erythroid cytopenias. New
information on the pathophysiology of CDA will be presented
during this symposium.
After attending this session, it
is expected that the learner will be able to:
1. Describe the biology of
erythropoiesis.
2. Describe the clinical presentation and molecular basis of
Diamond-Blackfan Anemia.
3. Describe the clinical presentation and pathophysiology of
congenital dyserythropoietic anemia.
-
Introduction: How
"Pure" Is Pure Red Blood Cell Aplasia?
Jeffrey M. Lipton, Schneider Children's Hospital, New Hyde Park, NY
-
Biology of Erythroid Development
Mitchell Weiss, Children's Hospital of Phiadelphia, Philadelphia, PA
-
Clinical and Molecular Biology of
Diamond-Blackfan Anemia
Adrianna Vlachos, Schneider Children's Hospital, New Hyde Park, NY
-
Congenital Dyserythropoietic
Anemias 2006: Where Are We Now?
Bertil E. Glader, Stanford University School of Medicine, Stanford, CA
-
Question and Answer Session
9:45am–11:45am
3305A—Rhabdomyosarcoma
ASPHO Symposium
Room 3020, Moscone West
Chairs: K. Scott Baker, University of Minnesota, Minneapolis, MN; and
Douglas Hawkins, Children's Hospital and Regional Medical
Center, Seattle, WA
This session will focus on
current results of recent clinical trials in the treatment of
rhabdomyosarcoma (RMS) and review progress made over the
consecutive Intergroup Rhabdomyosarcoma Study Group Trials and
current trials of the Soft Tissue Sarcoma Committee within
COG. The importance of radiation therapy to achieve local
control in the treatment of RMS, as well as some of the
controversies of radiation therapy in this disease, will be
discussed. New treatment modalities available for radiation
therapy delivery and their role in the treatment of RMS will
be reviewed. Finally, the session will end with a state of the
art update on current understanding of the biological and
molecular genetic features of RMS and their implications in
the diagnosis and treatment of children with RMS.
After attending this session, it
is expected that the learner will be able to:
1. Discuss current treatment
results of recent trials in the treatment of RMS.
2. Identify the importance of radiation therapy in the
management of RMS and describe new ways that this treatment
may be delivered.
3. Describe recent advances in the biology of RMS and how
these impact therapeutic decisions.
-
Introduction
K. Scott Baker, University of Minnesota, Minneapolis, MN
-
Lessons Learned About the Local
Control Issues and Radiation Therapy in the Management of
Childhood Rhabdomyosarcoma
Sarah S. Donaldson, Stanford Cancer Center, Stanford, CA
-
Clinical Trials in
Rhabdomyosarcoma: Current Results
Douglas Hawkins, Children's Hospital and Regional Medical Center,
Seattle, WA
-
Impact of Biology and Genetics on
the Diagnosis and Treatment of Rhabdomyosarcoma
Frederic Barr, University of Pennsylvania School of Medicine,
Philadelphia, PA
-
Question and Answer Session
11:00am–4:00pm
Commercial Exhibits Open and Posters
Available for Viewing
PAS Exhibits
Levels 1 and 2, Moscone West
Posters Available for Viewing:
11:00am–4:00pm
Author Attendance: 12:00pm–2:00pm
Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology
Level 2:
– Cardiology
– Neonatal Neurology
– Neonatology
12:00pm–2:00pm
Poster Session II
PAS Poster Session
Levels 1 and 2, Moscone West
Level 1:
– Allergy, Immunology and Rheumatology
– Developmental-Behavioral Pediatrics
– Endocrinology
– Infectious Diseases
– General Pediatrics
– Hematology–Oncology
Level 2:
– Cardiology
– Neonatal Neurology
– Neonatology
Includes
-
SPR Clinical Research Award:
Accelerated Development in the Visual Areas of Preterm
Infants? A Voxel-Based Morphometry Study on Diffusion
Tensor MR Imaging (DTI)
Maria Miranda, Copenhagen University Hospital, Hvidovre, Denmark
-
SPR Fellow's Basic Research
Award: Myopalladin Mutations and Inherited
Cardiomyopathies
Enkhsaikhan Purevjav, Baylor College of Medicine, Houston, TX
-
SPR Fellow's Clinical Research
Award: Novel Genotyping Technology To Classify Childhood
Leukemia
Joshua D. Schiffman, Stanford University, Palo Alto, CA
-
SPR House Officer Research Award:
Erythropoietin Protein Expression in the Developing Human
Eye
Shrena Patel, University of New Mexico, Albuquerque, NM
1:45pm–3:45pm
3650—Hematologic Issues in the PICU
PAS/ASPHO Topic Symposium
Room 3016-3018, Moscone West
Chairs: Roshni Kulkarni, Michigan State University, East Lansing, MI;
and Prasad Mathew, University of New Mexico, Albuquerque, NM
Target Audience: Pediatric
hematologists/oncologists, pediatric critical care physicians,
pediatric surgeons and basic science researchers in
hematology.
Critically ill children often
suffer complications related to hematological consequences of
the primary illness or injury. Timely realization of these by
critical care physicians and hematology consultants is key to
improving outcomes in critically ill children. During the past
decade, hematology research (particularly in coagulation and
thrombophilia) has given new information that will help
clinicians care for these children.
-
Introduction: Hematologic Issues
in the PICU
Prasad Mathew, University of New Mexico, Albuquerque, New Mexico
-
Disseminated Intravascular
Coagulation
Keith Hoots, The University of Texas Health Science Center and The
University of Texas M.D. Anderson Cancer Center, Houston,
TX
-
Massive Hemorrhage: A
Hematologists Perspective
Roshni Kulkarni, Michigan State University, East Lansing, MI
-
Thrombosis Including
Heparin-Induced Thrombocytopenia in the PICU
Guy Young, Children's Hospital of Orange County, Mattel Children's
Hospital at UCLA, Orange County, CA
-
Discussion
Sponsored jointly by
the American Society of Pediatric Hematology/Oncology and the
Pediatric Academic Societies
4:00pm–6:00pm
3800A—ASPHO Presidential Symposium and
Awards
ASPHO Presidential Lecture
Yerba Buena Gardens Salon 7, SF Marriott
Chair: F. Leonard Johnson, Oregon Health Sciences University, Portland,
OR
-
Welcome
F. Leonard Johnson, Oregon Health & Science University, Portland,
OR
-
ASPHO Young Investigator Award
Lectures:
-
Rac GTPases Regulate the
Morphology and Deformability of the Erythrocyte
Cytoskeleton
Theodosia A. Kalfa
-
Phosphorylation-Mediated Control
of Transcriptional Repression by the Myeloid
Translocation Gene Protein, MTG16: Implications for
Hematopoietic stem Cell Self-Renewal and
Leukemogenesis
Michael Engel
-
Frank A. Oski Memorial Lecture:
Cell–Cell Interactions in the Bone Marrow: How Basic
Studies in Stem Cell Biology Informed New Therapeutics in
Cancer and Gene Therapy
David A. Williams, Cincinnati Children's Hospital Medical Center,
Cincinnati, OH
-
Distinguished Career Award
Archie Bleyer, M. D. Anderson Cancer Center, Houston, TX
4:15pm–5:45pm
3810—RNA Interference, Technological
Development of siRNAs and Potential Treatments for Childhood
Diseases
PAS State of the Art Plenary
Room 3016-3018, Moscone West
Chair: R. Alan B. Ezekowitz, Harvard Medical School, Massachusetts
General Hospital, Boston, MA
Target Audience: Basic scientists
studying a broad range of childhood diseases, translational
scientists of all disciplines studying clinical implications
of basic science research, clinical scientists studying
childhood and other diseases in need of improved therapies and
clinicians interested in cutting-edge science and its medical
implications.
RNA interference is a recently
discovered, naturally occurring intracellular process that
regulates gene expression through the silencing of specific
mRNAs. Methods of harnessing this natural pathway are being
developed that allow the catalytic degradation of targeted
mRNAs using specifically designed complementary small
inhibitory RNAs (siRNA). siRNAs are being chemically modified
to acquire drug-like properties. Numerous recent high-profile
publications have provided proofs of concept that RNA
interference may be useful therapeutically. Much of the design
of these siRNAs can be accomplished bioinformatically, thus
potentially expediting drug discovery and opening new avenues
of therapy for many childhood diseases including uncommon
pediatric and orphan diseases. A discussion of the science
behind RNA interference will be followed by a presentation of
the potential practical issues in applying this technology to
disease. The program then describes two therapeutic programs
currently under way with applications to pediatric diseases. A
question-and-answer time will follow each discussion.
-
The Science of RNA Interference
John J. Rossi, Beckman Research Institute of City of Hope, Duarte, CA
-
RNA Interference and Its
Potential Applications for Controlling Disease
Judy Lieberman, CBR Institute for Biomedical Research and Harvard
Medical School, Boston, MA
-
Silencing the VEGF Pathway with
siRNAs and the Potential Application to Retinopathy of
Prematurity
Pamela Pavco, Sirna Therapeutics, Boulder, CO
-
siRNA as Therapy for Respiratory
Syncytial Virus
John P. DeVincenzo, University of Tennessee School of Medicine,
Memphis, TN
6:00pm–6:30pm
3920A—ASPHO Business Meeting
ASPHO Business Meeting
Yerba Buena Gardens Salon 7, SF Marriott
6:30pm–7:00pm
3960A—ASPHO Distinguished Career Award
Reception
ASPHO Reception
Golden Gate Hall C1, SF Marriott
7:00pm–9:00pm
3980A—Exploring von Willebrand Disease (VWD):
Approaches to Age- and Gender-Related Issues
ASPHO Industry Sponsored Symposium
Yerba Buena Gardens Salon 8, SF Marriott
Supported by a grant from ZLB Behring
Monday, May 1
7:00am–8:00am
4050A—Congenital Thrombotic
Thrombocytopenic Purpura (TTP) Registry
ASPHO Workshop
Golden Gate Hall A1, SF Marriott
Chair: David G. Motto, University of Michigan, Ann Arbor, MI
Last year we established that
there was interest in the pediatric hematology community to
establish a registry for patients with congenital TTP. This
year we will describe the formation of the registry and how
individual physicians can access it and contribute patient
information. This registry will contain descriptive
information regarding the presentation, diagnosis, treatment
and outcome of patients with congenital TTP, along with a
database of ADAMTS13 mutations. Information will also be
provided regarding where physicians can obtain clinical and
research laboratory testing for ADAMTS13 activity and mutation
analysis.
7:00am–8:00am
4060A—Pediatric Cancer—Pharmacogenetics
and Pharmacogenomics: Do They Have Practical Applications?
ASPHO Workshop
Golden Gate Hall A2-3, SF Marriott
Chairs: Brigitta U. Mueller, Baylor College of Medicine, Houston, TX;
and Craig A. Mullen, University of Rochester Medical Center,
Rochester, NY
This session will review genetic
polymorphisms related to drug metabolism and their
relationship to toxicity. Available pediatric data will be
reviewed specifically related to current recommendations for
genetic testing in relationship to specific agents, as well as
dose modifications. This program will also contain a case
review to highlight potential clinical scenarios in
relationship to pharmacogenetic testing.
-
Pharmacogenetics in Clinical
Trials
Lisa Bomgaars, Texas Children's Cancer Center, Houston, TX
-
Pharmacogenetics and Toxicity
Secondary to Cancer Therapy
Fatih Okcu, Texas Children's Cancer Center, Baylor College of Medicine,
Houston, TX
-
Case Discussion
8:15am–10:15am
4180A—Chronic Organ Damage in Sickle Cell
Disease: Diagnosis, Prevention and Treatment
ASPHO Symposium
Room 3016-3018, Moscone West
Chair: Russell E. Ware, St. Jude Children’s Hospital, Memphis, TN
Chronic organ damage is
increasingly recognized as an important source of morbidity
and mortality for young persons with sickle cell disease. This
symposium will include descriptions of several prospective
multicenter clinical trials that focus on the diagnosis,
treatment and prevention of organ damage in this common
hematological disorder.
After attending this session, it
is expected that the learner will be able to:
1. Discuss ongoing prospective
multicenter randomized clinical trials that focus on brain
damage in pediatric patients with sickle cell anemia.
2. Describe prospective clinical trials that focus on spleen
and kidney damage in very young patients with sickle cell
anemia.
3. Describe new imaging modalities for transfusional iron
overload in the liver and heart, as well as studies using new
oral iron chelating agents for its therapeutic management.
-
Introduction and Overview
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
-
Brain
-
Silent Infarct Transfusion (SIT)
Trial
Michael R. DeBaun, Washington University School of Medicine, St. Louis,
MO
-
Stroke with Transfusions Changing
to Hydroxyurea (SWiTCH) Trial
Russell E. Ware, St. Jude Children's Research Hospital, Memphis, TN
-
Spleen and Kidney
-
Splenic Function in Young
Children: Lessons from BABY HUG
Zora R. Rogers, The University of Texas Southwestern Medical Center,
Dallas, TX
-
Renal Function in Young Children:
BABY HUG, Toddler HUG
Sherri A. Zimmerman, Duke University Medical Center, Durham, NC
-
Liver and Heart
-
New Imaging Techniques for
Transfusional Iron Overload
Thomas D. Coates, Children's Hospital of Los Angeles, Los Angeles, CA
-
LOral Iron Chelators for the
Management of Transfusional Iron Overload
Alan R. Cohen, Children's Hospital of Philadelphia, Philadelphia, PA
-
Questions and Panel Discussion
10:15am–12:15pm
4340—Hematology/Oncology III
PAS/ASPHO Platform Session
Room 3016-3018, Moscone West
Chairs: Robert Iannone and Mignon Loh
12:00pm–1:00pm
4410A—23rd Annual Audrey K. Brown
Kernicterus Symposium
Club
Room 2003-2007, Moscone West
Chairs: David K. Stevenson, Stanford University School of Medicine,
Stanford, CA; William J. Cashore, Women and Infants Hospital
of Rhode Island, Providence, RI; and Vinod K. Bhutani,
Stanford University School of Medicine, Stanford, CA
-
Organic Anion Transporter Protein
2 Gene Polymorphisms and Neonatal Hyperbilirubinemia
Jon F. Watchko, Division of Newborn Medicine, Department of Pediatrics,
University of Pittsburgh School of Medicine, Pittsburgh,
PA
-
The Potential Role of Unbound
Bilirubin Measurements for the Management of Jaundiced
Newborns
Charles E. Ahlfors, L.W. Ligand, Vashon, WA
Contact for information:
David K. Stevenson, M.D.
Stanford University School of Medicine
Phone: 650-723-5711
E-mail: dstevenson@stanford.edu
Supported in part by an unrestricted educational grant from
Natus Medical, Inc.
12:45pm–2:45pm
4490A—Exploring Inhibitors: Hemophilia A,
Hemophilia B
ASPHO Industry Sponsored Symposium
Yerba Buena Gardens Salon 8, SF Marriott
Supported by a grant from ZLB Behring
3:00pm–5:00pm
4625A—Cancer Etiology
ASPHO Symposium
Room 3016-3018, Moscone West
Chairs: Doug K. Graham, University of Colorado at Denver and Health
Sciences Center, Denver, CO; and Julie A. Ross, University of
Minnesota, Minneapolis, MN
This program will highlight both
clinical and basic science research into the causes of
childhood cancer. The program will begin with an overview of
the epidemiology of childhood cancer including incidence,
trends and putative risk factors. Obstacles to conducting
well-designed studies in North America will be discussed, and
the establishment of a North American Childhood Cancer
Research Network will be introduced as a means to help address
some of these challenges. The program will follow with a
discussion of genetic susceptibility to childhood cancer from
single gene disorders with high individual risk but low
population frequency to common population polymorphisms with
low individual risk but high population frequency. In the
final presentation, the role the family of tyrosine kinases
has in the pathogenesis of childhood cancer will be addressed.
Current research on a novel receptor kinase, Mer, will be
presented to suggest a potential role of this proto-oncogene
in the development of pediatric T cell leukemia and lymphoma.
After this session, participants
should be able to:
1. Discuss the current state of
knowledge regarding the epidemiology of childhood cancer in
the United States.
2. Describe the major activities of the Childhood Cancer
Research Network.
3. Identify the role of genetic susceptibility in the
development of childhood cancer.
4. Describe the role of tyrosine
kinases in the pathogenesis of pediatric cancer, and discuss
how these oncogenes are being targeted in the development of
new drugs.
-
Introduction
Doug K. Graham, University of Colorado at Denver and Health Sciences
Center, Denver, CO
-
Causes of Childhood Cancer: Where
to Next?
Julie A. Ross, University of Minnesota, Minneapolis, MN
-
Genetic Susceptibility to
Cancer—The Weak and the Strong
Stella M. Davies, Cincinnati Children’s Hospital Medical Center,
Cincinnati, OH
-
Tyrosine Kinases as Oncogenes in
Pediatric Cancer: The Role of the Mer Receptor Tyrosine
Kinase in Lymphoblastic Leukemia and Lymphoma
Doug K. Graham, University of Colorado at Denver and Health Sciences
Center, Denver, CO
-
Question and Answer Session
|
